Hims & Hers Health Inc. (HIMS) stock surged 12.15% in Tuesday's trading session, driven by impressive third-quarter results and ambitious expansion plans. The telehealth company reported Q3 revenue of $600 million, surpassing analysts' expectations of $580.2 million, with its subscriber base growing 21% year-over-year to 2.47 million.

Investors were particularly excited about Hims & Hers' potential entry into the weight loss market. The company revealed it is in active talks with Novo Nordisk to offer Wegovy injections through its platform, with plans to potentially offer an oral version of the treatment once approved. This move could significantly expand the company's offerings in the rapidly growing weight loss segment.

Adding to the positive sentiment, CEO Andrew Dudum outlined the company's vision for global expansion during the earnings call. Hims & Hers plans to launch in Canada, Brazil, Japan, and the UK, capitalizing on what Dudum describes as a universal frustration with access to quality healthcare. The CEO emphasized the company's ambition to transform from a niche telehealth brand into a global lifestyle name, focusing on data-driven diagnostics and personalized care. With plans to cross the one million-square-foot threshold for compounding infrastructure by year-end, Hims & Hers is positioning itself for large-scale personalization and proactive health solutions.